cadenas

ITCC-047 REGORAFENIB

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

ITCC-047 REGORAFENIB

A multi-center, open-label, non-randomized, phase I dose escalation study of regorafenib (BAY 73-4506) in pediatric subjects with solid malignant tumors that are recurrent or refractory to standard therapy

Promotor Name : BAYER

Investigator Name : B. GEOERGER

Trial registered on clinicaltrial.gov: NCT02085148